2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

9:00AM-11:00AM: Abstract Number: 1751

Coagulation Pathway Function in Ischemia/Reperfusion Tissue Injury in Autoimmune Prone Mice

Systemic Lupus Erythematosus – Animal Models - Poster I

9:00AM-11:00AM: Abstract Number: 1396

Cognitive Function in Children with SLE Nephritis: A Cross-Sectional Comparison to Children with Other Glomerular Chronic Kidney Diseases

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster II: Myositis, Systemic Lupus Erythematosus, Sjögren's Syndrome

9:00AM-11:00AM: Abstract Number: 1455

Collagen-Induced Arthritis and Uveitis in Mice Lacking TNF Receptors

Rheumatoid Arthritis – Animal Models - Poster II

9:00AM-11:00AM: Abstract Number: 1454

Combination of the SYK Inhibitor, GS-9876, with a JAK Inhibitor Increases Efficacy in a Chronic Rat Model of Collagen-Induced Arthritis

Rheumatoid Arthritis – Animal Models - Poster II

9:00AM-11:00AM: Abstract Number: 1725

Combination Therapy of Apremilast and Biologic Agent As a Safe Option of Psoriatic Arthritis and Psoriasis

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1278

Combined Positron Emission Tomography and Magnetic Resonance Imaging in Assessing Gastrointestinal Involvement in Systemic Sclerosis: A Pilot Study

Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI

9:00AM-11:00AM: Abstract Number: 1107

Combining Scaffold-Free Cartilage Transplants to Controlled Gene Expression for Therapeutic Application in Rheumatic Disorders

Biology and Pathology of Bone and Joint - Poster II

9:00AM-11:00AM: Abstract Number: 1834

Commensal Ro60 Autoantigen Ortholog Cross-Reactivity in Human Lupus and Gnotobiotic Models

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster I

9:00AM-11:00AM: Abstract Number: 1550

Comorbidities of Rheumatoid Arthritis: Results from the Korean National Health and Nutrition Examination Survey

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1739

Comparative Effectiveness of Secukinumab and Adalimumab in Ankylosing Spondylitis As Assessed By Matching-Adjusted Indirect Comparison: An Analysis Based on All Pivotal Phase 3 Clinical Trial Data

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1596

Comparative Effectiveness of Tocilizumab Monotherapy with Tumor Necrosis Factor Inhibitors in Combination with Methotrexate in Patients with Rheumatoid Arthritis and Prior Exposure to Tumor Necrosis Factor Inhibitors

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1475

Comparative Risk of Cardiovascular Outcomes Between Topical and Oral Non-Selective Nsaids in Taiwanese Rheumatoid Arthritis Patients

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1656

Compare the Potential of Osteoclast Precursors (OCPs) Residing in Bone Marrow and Peripheral Blood As the Surrogates of Psoriasis Pathogenesis

Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster I

9:00AM-11:00AM: Abstract Number: 1472

Comparison Between Carotid Plaque and Carotid Intima-Media Thickness to Detect Subclinical Atherosclerosis in Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1488

Comparison Between Carotid Ultrasonography and Coronary Artery Calcification Score to Detect Subclinical Atherosclerosis in Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].